Exploring Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure (PGE2)

Zhejiang University

Status: Completed

Conditions: Acute-On-Chronic Liver Failure; Cirrhosis and Chronic Liver Disease

Treatments: Diagnostic Test: plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.

Study type: Observational

Funder types: Other

Identifiers

NCT02965560

tclouds

Details and patient eligibility

About

Acute-on-chronic liver failure (ACLF) is an ailment with high incidence of multiorgan failure (MOF) and consequent mortality. Systemic inflammation and susceptibility to infection are characteristic pathophysiological features. Prostaglandin E2 (PGE2) could subdue systemic inflammation and alleviate liver injury in mice model. However, there are no studies evaluating PGE2 as a predictor of early mortality.This study is designed to investigate whether plasma PGE2 and its receptors are associated with development of MOF and predict short-term mortality in patients with acute-on-chronic liver failure. By the way, we will also measure several other potential predictive factors (C-reactive protein,severe hyponatremia, Second infections,Diabetes mellitus,High density lipoprotein,interleukin-10,serum bile acids,ferritin,the neutrophil to lymphocyte ratio,soluable urokinase plasminogen activator receptor,vWF-Ag levels and FVIII-to-PC ratios).

Enrollment: 350 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of acute-on-chronic liver failure according to Asian-Pacific Association for the Study of the Liver (APASL) diagnostic criteria

Exclusion criteria

• Hepatocellular carcinoma(HCC)
• Portal vein thrombosis
• Pregnancy
• Human immunodeficiency virus (HIV)
• Patients who had received immunomodulator,or cytotoxic/immunosuppressive therapy within at least the preceding 12 months

Trial design

350 participants in 1 patient group

HC,CHB,AD,ACLF

Description:

HC healthy controls; CHB chronic hepatitis B; AD acute decompensated cirrhosis; ACLF acute-on-chronic liver failure.

Treatment:

Diagnostic Test: plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.